<rst>
<header>
	<relations>
			<rel name="purpose" type="rst"/>
			<rel name="background" type="rst"/>
			<rel name="elaboration" type="rst"/>
			<rel name="circumstance" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="restatement" type="rst"/>
			<rel name="attribution" type="rst"/>
			<rel name="contrast" type="multinuc"/>
			<rel name="joint" type="multinuc"/>
			<rel name="same_unit" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1001" relname="preparation">1. Introduction</segment>
<segment id="2" parent="1003" relname="span">Cutaneous squamous cell carcinoma</segment>
<segment id="3" parent="2" relname="restatement">( cSCC )</segment>
<segment id="4" parent="1002" relname="same_unit">is the second most common type of cancer with an annual incidence of over one million globally .</segment>
<segment id="5" parent="1006" relname="span">Chronic ultraviolet</segment>
<segment id="6" parent="5" relname="restatement">( UV )</segment>
<segment id="7" parent="1007" relname="span">exposure was suggested to be responsible for DNA damage of normal keratinocytes in the epidermis ,</segment>
<segment id="8" parent="7" relname="elaboration">which leads to the development of skin cancers including cSCC .</segment>
<segment id="9" parent="1009" relname="preparation">However , the detailed underlying molecular mechanisms for this transition still need to be fully elucidated .</segment>
<segment id="10" parent="1010" relname="span">Apoptosis is one type of programmed cell death ,</segment>
<segment id="11" parent="1011" relname="joint">which is initiated by intrinsic or extrinsic signals</segment>
<segment id="12" parent="1012" relname="span">and finely-tuned by many factors</segment>
<segment id="13" parent="12" relname="elaboration">including BCL-2 family proteins .</segment>
<segment id="14" parent="1015" relname="span">BCL-2 family members , including both anti-apoptotic and pro-apoptotic BCL-2 family proteins , govern mitochondrial outer membrane permeabilization</segment>
<segment id="15" parent="14" relname="restatement">( MOMP )</segment>
<segment id="16" parent="1015" relname="purpose">to regulate apoptosis .</segment>
<segment id="17" parent="1018" relname="circumstance">When apoptotic cell death program starts ,</segment>
<segment id="18" parent="1018" relname="joint">MOMP releases cytochrome c to cytosol</segment>
<segment id="19" parent="1019" relname="span">and activates caspase-family proteases</segment>
<segment id="20" parent="19" relname="purpose">for initiating apoptotic events .</segment>
<segment id="21" parent="1022" relname="span">Tumors develop effective mechanisms</segment>
<segment id="22" parent="21" relname="purpose">to resist apoptosis</segment>
<segment id="23" parent="1009" relname="joint">and thus become one of the hallmark features of cancer .</segment>
<segment id="24" parent="1026" relname="span">The lead member BCL-2 and its homologue BCL-XL</segment>
<segment id="25" parent="24" relname="restatement">( BCL2L1 )</segment>
<segment id="26" parent="1025" relname="same_unit">are featured by the presence of four conserved BH domains ,</segment>
<segment id="27" parent="1025" relname="elaboration">three of which , BH1 , BH2 , and BH3 domains , are responsible for their antiapoptotic role mainly by interactions with other proapoptotic members of the BCL-2 family .</segment>
<segment id="28" parent="1028" relname="contrast">Inhibiting the activities of anti-apoptotic BCL-2 members by drugs</segment>
<segment id="29" parent="1029" relname="span">or neutralizing by BH3 peptides</segment>
<segment id="30" parent="1030" relname="same_unit">to prime cancer cells to death</segment>
<segment id="31" parent="1030" relname="same_unit">has been regarded as effective therapeutic modalities .</segment>
<segment id="32" parent="1031" relname="contrast">In another way , transcriptionally or post-transcriptionally repressing the expression levels of anti-apoptotic BCL-2 members in cancer is also promising .</segment>
<segment id="33" parent="1033" relname="span">However , the mechanism</segment>
<segment id="34" parent="33" relname="elaboration">regulating the expression of BCL-2 family members still remain unclear .</segment>
<segment id="35" parent="1035" relname="span">Autophagy is an evolutionarily-conserved catabolic process ,</segment>
<segment id="36" parent="1036" relname="joint">during which “ useless ” proteins and damaged organelles are sequestrated into autophagosomes</segment>
<segment id="37" parent="1037" relname="span">and fused with lysosomes</segment>
<segment id="38" parent="37" relname="purpose">to form autolysosomes for bulk degradation of embedded components .</segment>
<segment id="39" parent="1040" relname="span">Except the dysregulated autophagic process</segment>
<segment id="40" parent="39" relname="elaboration">defined as type II programmed cell death ,</segment>
<segment id="41" parent="1039" relname="same_unit">autophagy is generally regarded as protective cellular process .</segment>
<segment id="42" parent="1032" relname="joint">The recycled peptides , nucleotides and lipids together with the energy are critical to the maintenance of cellular homeostasis</segment>
<segment id="43" parent="1043" relname="span">and support tumor cells</segment>
<segment id="44" parent="43" relname="purpose">to survive under stressful environment .</segment>
<segment id="45" parent="1045" relname="span">Autophagy-related genes</segment>
<segment id="46" parent="45" relname="elaboration">( ATGs ) ,</segment>
<segment id="47" parent="1047" relname="span">including ULK1</segment>
<segment id="48" parent="47" relname="elaboration">( ATG1 ) , ATG3 , and ATG12 etc. , are involved in the distinct stages of autophagy :</segment>
<segment id="49" parent="1048" relname="joint">initiation , autophagosome nucleation , autophagosome membrane expansion , fusion with lysosome and the intravesicular components degradation .</segment>
<segment id="50" parent="1051" relname="attribution">Signaling pathways or critical factors are involved</segment>
<segment id="51" parent="1051" relname="span">in regulating ATG genes ,</segment>
<segment id="52" parent="51" relname="elaboration">including Class III PI3-kinase complex I , mTORC I complex , mTORC II complex and Beclin1 et al. .</segment>
<segment id="53" parent="1053" relname="span">However , the transcriptional regulation of the ATG genes is not fully explored .</segment>
<segment id="54" parent="1055" relname="span">In our previous study , Homeobox A9</segment>
<segment id="55" parent="54" relname="restatement">( HOXA9 ) was significantly downregulated</segment>
<segment id="56" parent="1054" relname="joint">and identified as tumor suppressor in cSCC tumors and cells .</segment>
<segment id="57" parent="1057" relname="span">HOXA9 functions</segment>
<segment id="58" parent="1058" relname="span">in repressing the proliferation , migration and invasiveness ,</segment>
<segment id="59" parent="58" relname="circumstance">while promoting apoptosis of cSCC cells .</segment>
<segment id="60" parent="1060" relname="span">However , the mechanisms</segment>
<segment id="61" parent="1061" relname="joint">about how HOXA9 regulate apoptosis has not been explored</segment>
<segment id="62" parent="1061" relname="joint">and remain to be elucidated .</segment>
<segment id="63" parent="1064" relname="attribution">In this study , we found</segment>
<segment id="64" parent="1065" relname="span">RELA</segment>
<segment id="65" parent="64" relname="elaboration">( p65 subunit of NF-κB )</segment>
<segment id="66" parent="1064" relname="same_unit">is transcriptionally repressed by HOXA9 .</segment>
<segment id="67" parent="1067" relname="span">In cSCC , RELA transactivates BCL-XL</segment>
<segment id="68" parent="1069" relname="span">to antagonize apoptosis and ATG genes</segment>
<segment id="69" parent="68" relname="elaboration">( ULK1 , ATG3 , and ATG12 )</segment>
<segment id="70" parent="1069" relname="purpose">to promote autophagy .</segment>
<segment id="71" parent="1071" relname="span">Our study highlights a HOXA9-NF-κB axis regulates both the apoptosis and autophagy</segment>
<segment id="72" parent="71" relname="purpose">to promote tumor development in cSCC ,</segment>
<segment id="73" parent="1071" relname="elaboration">which may suggest novel intervention targets for cSCC therapy .</segment>
<group id="1000" type="span" />
<group id="1001" type="span" parent="1000" relname="span"/>
<group id="1002" type="multinuc" parent="1004" relname="preparation"/>
<group id="1003" type="span" parent="1002" relname="same_unit"/>
<group id="1004" type="span" parent="1001" relname="span"/>
<group id="1005" type="multinuc" parent="1008" relname="background"/>
<group id="1006" type="span" parent="1005" relname="same_unit"/>
<group id="1007" type="span" parent="1005" relname="same_unit"/>
<group id="1008" type="span" parent="1004" relname="span"/>
<group id="1009" type="multinuc" parent="1008" relname="span"/>
<group id="1010" type="span" parent="1009" relname="joint"/>
<group id="1011" type="multinuc" parent="10" relname="elaboration"/>
<group id="1012" type="span" parent="1011" relname="joint"/>
<group id="1014" type="span" parent="1009" relname="joint"/>
<group id="1015" type="span" parent="1014" relname="span"/>
<group id="1017" type="span" parent="1009" relname="joint"/>
<group id="1018" type="multinuc" parent="1017" relname="span"/>
<group id="1019" type="span" parent="1018" relname="joint"/>
<group id="1022" type="span" parent="1009" relname="joint"/>
<group id="1024" type="span" parent="1009" relname="joint"/>
<group id="1025" type="multinuc" parent="1024" relname="span"/>
<group id="1026" type="span" parent="1025" relname="same_unit"/>
<group id="1028" type="multinuc" parent="1009" relname="joint"/>
<group id="1029" type="span" parent="1028" relname="contrast"/>
<group id="1030" type="multinuc" parent="29" relname="purpose"/>
<group id="1031" type="multinuc" parent="1009" relname="joint"/>
<group id="1032" type="multinuc" parent="1031" relname="contrast"/>
<group id="1033" type="span" parent="1032" relname="joint"/>
<group id="1035" type="span" parent="1032" relname="joint"/>
<group id="1036" type="multinuc" parent="35" relname="elaboration"/>
<group id="1037" type="span" parent="1036" relname="joint"/>
<group id="1039" type="multinuc" parent="1032" relname="joint"/>
<group id="1040" type="span" parent="1039" relname="same_unit"/>
<group id="1043" type="span" parent="1032" relname="joint"/>
<group id="1045" type="span" parent="1032" relname="joint"/>
<group id="1046" type="span" parent="1032" relname="joint"/>
<group id="1047" type="span" parent="1048" relname="preparation"/>
<group id="1048" type="multinuc" parent="1046" relname="span"/>
<group id="1050" type="span" parent="1048" relname="joint"/>
<group id="1051" type="span" parent="1050" relname="span"/>
<group id="1053" type="span" parent="1048" relname="joint"/>
<group id="1054" type="multinuc" parent="53" relname="elaboration"/>
<group id="1055" type="span" parent="1054" relname="joint"/>
<group id="1056" type="multinuc" parent="1048" relname="joint"/>
<group id="1057" type="span" parent="1056" relname="contrast"/>
<group id="1058" type="span" parent="57" relname="circumstance"/>
<group id="1059" type="multinuc" parent="1056" relname="contrast"/>
<group id="1060" type="span" parent="1059" relname="joint"/>
<group id="1061" type="multinuc" parent="60" relname="elaboration"/>
<group id="1063" type="span" parent="1059" relname="joint"/>
<group id="1064" type="multinuc" parent="1063" relname="span"/>
<group id="1065" type="span" parent="1064" relname="same_unit"/>
<group id="1067" type="span" parent="1059" relname="joint"/>
<group id="1068" type="span" parent="67" relname="purpose"/>
<group id="1069" type="span" parent="1068" relname="span"/>
<group id="1070" type="span" parent="1059" relname="joint"/>
<group id="1071" type="span" parent="1070" relname="span"/>
	</body>
</rst>
